BSG and neoplasm: While transient gene expression technologies may be sufficient in expressing these proteins, an alternative technology originally intended for generation of a stable cell line like the FRT/ Flp-InTM recombinase system has been employed successfully to express a tumour-associated antigen, HAb18G/CD147, for functional studies [118].